Related Experiment Video
Updated: Jul 1, 2025
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
Nanomaterials Boost CAR-T Therapy for Solid Tumors
Jun Long1, Yian Wang2, Xianjie Jiang3
1Shenzhen Geim Graphene Center, Tsinghua-Berkeley Shenzhen Institute & Tsinghua Shenzhen International Graduate School, Tsinghua University, 1001 Xueyuan Road, Shenzhen, 518055, China.
Abstract:
T cell engineering, particularly via chimeric antigen receptor (CAR) modifications for enhancing tumor specificity, has shown efficacy in treating hematologic malignancies. The extension of CAR-T cell therapy to solid tumors, however, is impeded by several challenges: The absence of tumor-specific antigens, antigen heterogeneity, a complex immunosuppressive tumor microenvironment, and physical barriers to cell infiltration. Additionally, limitations in CAR-T cell manufacturing capacity and the high costs associated with these therapies restrict their widespread application. The integration of nanomaterials into CAR-T cell production and application offers a promising avenue to mitigate these challenges. Utilizing nanomaterials in the production of CAR-T cells can decrease product variability and lower production expenses, positively impacting the targeting and persistence of CAR-T cells in treatment and minimizing adverse effects. This review comprehensively evaluates the use of various nanomaterials in the production of CAR-T cells, genetic modification, and in vivo delivery. It discusses their underlying mechanisms and potential for clinical application, with a focus on improving specificity and safety in CAR-T cell therapy.
Insights
Nanomaterials can improve chimeric antigen receptor (CAR)-T cell therapy for solid tumors by enhancing specificity and reducing costs. This approach addresses challenges in CAR-T cell production and delivery for better cancer treatment outcomes.
Area of Science:
- Immunology
- Biotechnology
- Materials Science
Background:
- Chimeric antigen receptor (CAR)-T cell therapy shows promise for hematologic malignancies.
- Significant challenges hinder CAR-T cell efficacy in solid tumors, including antigen scarcity, tumor microenvironment complexity, and manufacturing limitations.
- Current CAR-T cell therapies face high costs and production constraints.
Purpose of the Study:
- To review the application of nanomaterials in CAR-T cell therapy for solid tumors.
- To explore how nanomaterials can overcome existing challenges in CAR-T cell production, targeting, and delivery.
- To assess the potential of nanomaterials to improve CAR-T cell specificity, persistence, and safety.
Main Methods:
- Comprehensive literature review on nanomaterial integration in CAR-T cell therapy.
- Analysis of mechanisms underlying nanomaterial-enhanced CAR-T cell functions.
- Evaluation of nanomaterial applications in CAR-T cell genetic modification and in vivo delivery.
Main Results:
- Nanomaterials can decrease variability and cost in CAR-T cell production.
- Integration of nanomaterials can enhance CAR-T cell targeting, persistence, and reduce adverse effects.
- Nanomaterials offer potential solutions for improving CAR-T cell therapy in solid tumors.
Conclusions:
- Nanomaterial integration presents a promising strategy to advance CAR-T cell therapy for solid tumors.
- Further research into nanomaterial applications can improve CAR-T cell specificity, safety, and clinical applicability.
- Addressing manufacturing and delivery challenges with nanomaterials could broaden access to effective CAR-T cell treatments.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...